checkAd
    Startseite > Aktien > CRISPR Therapeutics > Nachrichten
    CRISPR Therapeutics Aktie
    50,45
     
    EUR
    -3,44 %
    -1,80 EUR
    Letzter Kurs 25.04.24 Lang & Schwarz
    49,40
     
    EUR
    128 STK
    Geldkurs 25.04.24
    51,50
     
    EUR
    128 STK
    Briefkurs 25.04.24
    ISIN: CH0334081137 · WKN: A2AT0Z · Schweiz

    Neueste Nachrichten

    CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
    22.04.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
    03.04.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
    01.04.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics Proposes New Appointment to the Board of Directors
    13.03.24 · globenewswire · CRISPR Therapeutics
    wO Börsenlounge: Block | Telekom | Allianz - zu den Glorreichen Sieben kommen die Sieben Samurai
    23.02.24 · Markus Weingran · Allianz
    CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    21.02.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
    15.02.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics Announces $280 Million Registered Direct Offering
    13.02.24 · globenewswire · CRISPR Therapeutics
    European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
    13.02.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics-Aktie: Neuer Rückenwind?
    17.01.24 · Sharedeals · CRISPR Therapeutics
    CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
    16.01.24 · globenewswire · CRISPR Therapeutics
    CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
    08.01.24 · globenewswire · CRISPR Therapeutics